Category: Colon cancer

Home / Established Year

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

  June 2024: The Food and Drug Administration has given accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) in combination with cetuximab for adults who have KRAS G12C-mutated locally advanced or metasta..

Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer

Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer

The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic colorectal cancer (mCRC) who have undergone specific prior treatments.Efficac..

Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer

Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer

The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic colorectal cancer (mCRC) who have undergone specific prior treatments.The ef..

Colorectal cancer awareness month
,

March month is colorectal cancer awareness month

March 2023: In 2020, nearly 2 million cases of colorectal cancer will be diagnosed globally, making it the third most prevalent cancer type. It is the second leading cause of cancer-related deaths, accounting for nearly 1 million..

OG-Tukysa-logo
, , , , ,

Accelerated approval is granted by FDA to tucatinib with trastuzumab for colorectal cancer

In February 2023, the Food and Drug Administration (FDA) sped up the approval of tucatinib (Tukysa, Seagen Inc.) and trastuzumab for the treatment of RAS wild-type HER2-positive colorectal cancer that has spread or can not be rem..

, , , ,

All participants in a small cancer trial achieved complete remission

June 2022: A small study of rectal cancer patients yielded extraordinary results: 100 percent of the individuals were in remission. The results were published in The New England Journal of Medicine this week.The trial was funded ..

, ,

Weight loss is linked to decreased risk of colon and rectal polyps

May 2022: According to study findings published February 1 in the Journal of the National Cancer Institute, overweight or obese adults who lose more than 5 pounds over five years have a 46 percent lower risk of developing precanc..

Colorectal cancer latest screening guidelines

July 6th 2021 : Colorectal cancer is the among most prevalent cause of cancer death in the the world. Regular screening, on the other hand, can detect colorectal cancer while it is tiny, hasn't spread, and may be easier to treat...

Gastrointestinal stromal tumor targeting drug Avapritinib

Gastrointestinal stromal tumor targeting drug Avapritinib (Avapriny, Ayvakit, BLU-285) is approved by USFDA on 9th January, 2020. The drug covers two indications: for the treatment of adult patients with inoperable resection or m..

Colorectal cancer PD-1 / PD-L1 treatment

Colon cancer immunotherapy, rectal cancer immunotherapy, colorectal cancer immunotherapy, and colorectal cancer PD-1 / PD-L1 treatment. Seventeen years ago, the number of drugs available for advanced colorectal cancer was very li..

Newer
Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy